Behavioral practices of patients with multiple sclerosis during Covid-19 pandemic.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, China, in late 2019 and Covid-19, a disease caused by SARS-CoV-2 became a pandemic in March 2020. As the pandemic still unfolds, uncertainty circles around the impact of SARS-CoV-2 infection on patients with chronic diseases, including autoimmune diseases such as multiple sclerosis (MS). To diminish the risk of SARS-CoV-2 infection and lessen the impact of the Covid-19 pandemic on the healthcare of MS patients, it is essential to understand knowledge, attitudes, and various behavioral practices related to Covid-19 among MS patients. Therefore, this study aimed to look at the behavioral practices related to Covid-19 among patients with MS. A total of 176 MS patients diagnosed at least one year before the survey were conveniently sampled online in Saudi Arabia and their data collected using a structured interview questionnaire in electronic Google form. We determined the reliability of the questionnaire by measuring its internal consistency in a pilot sample of 30 participants. Overall, more than 80% of participants had good knowledge and attitudes towards Covid-19. However, this did not correlate well with the impact on healthcare (r = 0.06). Our study revealed that 46% of participants were anxious about taking their medication, and 32% of participants missed their hospital appointments. Furthermore, 15% of the participants had a relapse but did not go to the hospital because of the pandemic, 15.9% stopped their DMTs, and 35.2% missed drug infusions or refills. Our study revealed overall good knowledge and attitudes related to Covid-19 among MS patients. However, the healthcare impact was considerable, as 32% of the participants missed their hospital appointments, and another 15% had a relapse. This highlights the significance of the impact of the Covid-19 pandemic on the healthcare of patients with MS. Measures to mitigate the effect of the pandemic on healthcare service delivery to patients with MS, such as telemedicine, should be strongly encouraged.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered in Wuhan, China, in late 2019. Covid-19, a disease caused by SARS-CoV-2 quickly spread and was officially declared a pandemic on March 11, 2020 [1]. On March 2, 2020, the Ministry of Health in Saudi Arabia announced the first confirmed case of Covid-19 in the Kingdom of Saudi Arabia. Since then, the number of cases has steadily increased. As of July 8, 2020, the total number of confirmed cases had reached 220,000, the highest among all the Arabian Gulf States, with 158,000 recoveries and 2059 deaths [2]. As a result of the rapid increase in the number of Covid-19 cases in Saudi Arabia, knowledge, attitudes, and practices related to Covid-19 among citizens will play an essential role in the control of the impact of the Covid-19 pandemic. This is even more essential in populations at high risk of acquiring SARS-CoV-2 infection and to whom the course of Covid-19 would be worrisome, such as patients who require immunosuppressive/immunomodulatory drugs, including patients known to have Multiple Sclerosis (MS) [3].

MS is an immune-mediated inflammatory demyelinating disease of the central nervous system that affects more than 2 million people around the world and a major cause of severe neurological disability in adult life [4]. Recent studies suggested a moderate-to-high prevalence of MS in the Middle East and in North African countries [5]. Patients with MS require long-term treatment with disease-modifying therapy (DMT) to help control their disease course and decrease the rates of relapse. The type of DMT may differentially affect the risk profile of MS patients with the lowest risk of infections being associated with interferon beta [6, 7]. Some conflicting evidence, however, revealed that most disease-modifying therapies for MS do not particularly target the innate immune system, which confers protection against SARS-CoV-2, and few have any major long-term impact on CD8 T cells to limit protection against Covid-19 [8]. Some other researchers have also shown that immunosuppressive therapy neither appears to have a significant consequence on infection with SARS-CoV-2 nor seems to marshal a severe disease course in many cases [9, 10]. However, it is generally agreed that some drugs, such as interferons, glatiramer acetate, and teriflunomide seem to be safe. On the other hand, B-cell-depleting DMTs, and DMTs which cause lymphopenia such as cladribine, alemtuzumab, and dimethyl fumarate, are cautioned [9, 11]. With the inconclusive evidence of the effect of DMTs on the frequency of SARS-CoV-2 infection and the course of Covid-19, including the serious Covid-19 complications, the decision on whether to discontinue treatment, switching or timing of infusion therapy could be a source of uncertainty to both the patient and the attending physician. Many researchers and organizations have attempted to make recommendations regarding the effect of DMTs on Covid-19, but the evidence is at times conflicting, and a source of confusion [12, 13]. In one survey involving practicing neurologists in North America, a significant proportion of respondents believed that patients with MS are at higher risk of acquiring Covid-19 than the general population. Furthermore, 23% of the respondents were aware that their patients have self-discontinued treatment with disease-modifying therapy due to the fear of SARS-Cov-2 infection, with some doing so against medical advice [14]. With the recent lockdown and postponement of non-essential services in Saudi Arabia, patients with MS may have limited access to routine healthcare services, either because of unavailability or the fear of SARS-CoV-2 infection. Thus, in a challenging time like this, vulnerable groups such as MS patients may be further compromised by the inadequacy of the healthcare system, which put them at considerable risk of relapse and severe neurological symptoms [15].

We conducted this study among individuals known to have MS for at least the past year, living in Saudi Arabia. This study aimed to determine the level of knowledge of the Covid-19 pandemic and attitudes regarding Covid-19 in order to evaluate the extent of the impact Covid-19 has on the healthcare of MS patients and their daily lives. We focused on the effects of the spread of the virus on the patients’ hospital visits, medication administration, psychosocial implications, risk of acquiring the SARS-Cov-2 infection, and finally, the appropriate preventive behaviors.

Materials and methods

Study design

We conducted a descriptive cross-sectional survey to evaluate knowledge, attitudes, and practices related to the Covid-19 pandemic in MS patients living in Saudi Arabia. This survey took place in June 2020, during the peak of the Covid-19 pandemic in the Kingdom of Saudi Arabia. Our study was conducted during the curfew in Saudi Arabia. We included MS patients who, during our study period, had been diagnosed with MS for at least one year.

Study participants and recruitment

Since this was a descriptive cross-sectional study, the sample size was determined by a convenient sampling technique, based on the availability of MS patients. A total of 176 patients agreed to participate. An electronic Google form was sent to the participants. The questionnaire was sent through WhatsApp and posted on the Twitter account of the principal investigator in addition to two other MS neurologists practicing in Saudi Arabia. An informed written consent was included at the beginning of the survey. To ensure patients privacy, no personal identifications were included in the form and responses were encrypted to protect the data.

Data collection and statistical analysis

Data were collected using a structured interview questionnaire. The questionnaire was designed by the authors to cover issues related to the Covid-19 pandemic on people living with MS. The survey questions were based on emerging COVID-19 reports, guidelines, clinical experience, and incorporated patients' inquiries during the pandemic. Eligible participants had to answer questions about their demographic details, disease duration, and type of medications used. This was followed by three sections to assess knowledge, attitude, and practices related to the COVID-19 pandemic. Knowledge was assessed by three questions based on Covid-19 symptomatology and preventive measures. Score 3,2,1 for Yes, To some extent and No respectively, maximum score is 9 and minimal score is 3. Score above 7 were considered as good knowledge and score above 3 as average and 3 as poor knowledge. Attitudes were assessed by asking participants about hand washing, social distancing, and quarantine rules. Answers graded 3,2,1, for always, sometimes and never respectively with score above 7 were considered as good attitude. Practices related to Covid-19 were assessed by asking seven questions about the impact of Covid-19 on practices related to the clinical management of MS. The responses were scaled Yes, To some extent and No with 3, 2,1 respectively and reversing the score for negative item. The questionnaire's reliability was assessed by measuring its internal consistency, which was done by pre-testing the survey on a small sample of the study population (30 participants). Internal consistency reliability was measured using IBM SPSS 23.0 software to determine Cronbach's Alpha value for each part, and the questionnaire was reliable if Cronbach's Alpha value was found to be ≥0.7 in all of the three sections of the questionnaire. Results showed that all the three sections showed internal consistency with Cronbach's Alpha value of ≥0.7 after some adjustments in the questions were made.

The responses to the questionnaires were extracted from Google Forms and exported to Microsoft Excel for coding. The coded data were exported to SPSS version 23 for analysis. We calculated descriptive statistics (means with SDs and percentage frequencies) to characterize the distribution of the study results. We received a total of 192 responses. After reviewing 16 responses were excluded because of duplication or missing responses.

Ethical approval

The study received ethical approval from the King Abdul-Aziz University Hospital's Institutional Review Board.

Results

(Table 1: Demographic and other various characteristics of participants) summarizes the demographic characteristics of the participants. A total of 176 patients with MS responded to the questionnaire. Of the 176, 122 (69%) participants were female, with a mean age of 32±9.2 years. Out of 176 participants, 168 (95.5%) had relapsing-remitting multiple sclerosis (RRMS), and a small percentage had primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS). The disease duration ranged from 1 to 25 years, with a mean duration of 5.5±5.1 years. Most of the patients were on disease-modifying therapy (92%). The most frequently prescribed medications were injectable interferons (26%), followed by Ocrelizumab (20.5%), while the least-used therapy was Almetuzemab (1.1%) (Fig 1). A majority of the participants (75%) were dependent on governmental health care systems for medication and follow-up, 20% had private insurance, and only 4.5% paid for their health care out of pocket.

Table 1

Demographic and other various characteristics of participants.

Variables	Percentages
Age (Years)	Mean ± SD
	32.51±9
Sex
Male	54 (30.7%)
Female	122 (69.3%)
Education
High School	30 (17%)
Bachelor	114 (64.8%)
Post-graduate	32 (18.2%)
Employment
Employed	104 (59.1%)
Unemployed	72 (40.9%)
Type of MS
RRMS	168 (95.5%)
PPMS	4 (2.3%)
SPMS	4 (2.3%)
Duration of the disease (Years)	(Mean ± SD)
	5.5 ± 5
Medication provider
Governmental hospital	132 (75.0%)
Private insurance	36 (20.5%)
Own expense	8 (4.5%)

MS; Multiple Sclerosis, RRRM; Relapsing-Remitting Multiple Sclerosis, PPMS; Primary-Progressive Multiple Sclerosis, SPMS; Secondary-Progressive Multiple Sclerosis, PRMS; Progressive-Relapsing Multiple Sclerosis.

Fig 1

Types of disease-modifying therapy used by participants.

COVID-19 knowledge among MS patients

The mean knowledge score was 8.6, and 92.1% scored above 8, which is considered sufficient knowledge. All the patients were aware of the pandemic, and 168 (95%) of the participants knew that there was a pre-symptomatic period. Regarding the knowledge about precautions required to prevent the spread of Covid-19, 158 (89.8%) participants understood the precautions. Some participants, 18 (10.2%), knew the precautions to some extent, and none of the participants did not understand preventive measures at all.

Attitudes related to Covid-19 among MS patients

Our participants had a good attitude overall. The majority of participants (n = 146, 83%) knew and followed the ministry of health home quarantine instructions. Of all participants, 158 (89.8%) mentioned that they regularly washed their hands. Most participants, that is 148 (84.1%), followed social distancing rules regularly. Concerning the quarantine guidelines, 144 (81.8%) participants responded that they always stayed at home.

Healthcare practices during the Covid-19 pandemic among MS patients

In assessing the impact of the Covid-19 pandemic on the healthcare of patients with MS, 94 (53.4%) participants stated that they do not have any fear or concern with continuing their disease-modifying therapy and, 48 (27.3%) had some fear, while only 34 (19.3%) were anxious about taking their medications. Of all participants, only 28 (15.9%) completely stopped taking their medications because of the fear of Covid-19 and 10 (5.7)% stopped taking their medication to some extents which mean poor compliance, but only 6 (3.4%) participants asked their doctors to discontinue or change their disease-modifying therapy and 2 (1.1%) stated that to some extent they raised concerns to their to doctors. Regarding the effect of the curfew hours on accessibility to health care facilities, 76 (43.2%) participants had to miss or cancel their appointments, and 56 (31.8%) participants missed their appointments because they wanted to avoid any possible source of SARS-Cov-2 infection. It is also worth noting that 26 (15%) participants mentioned they had a relapse and did not go to the hospital because of the Covid-19 pandemic. Another 62 (35%) participants mentioned that their infusion therapy date or medication refill was delayed because of the Covid-19 pandemic. (Table 2 summarizes the responses of the participants).

Table 2

Participants’ responses.

Part 1: Participants’ knowledge related to Covid-19.
Did you know that it may take up to 10 days to develop symptoms?	Yes 168 (95.5%)
	To some extent 8 (4.5%)
Do you know the precautions needed to avoid infection with Covid-19?	Yes 158 (89.8%)
	To some extent 18 (10.2%)
Do you follow MOH quarantine instructions?	Yes 146 (83%)
	To some extent 30 (17%)
Part 2: Participants’ attitudes related to Covid-19.
Do you wash your hands regularly?	Always 158 (89.8%)
	Sometimes 18 (10.2%)
Do you follow social distancing rules?	Always 148 (84.1%)
	Sometimes 28 (15.9%)
Do you stay home all the time?	Always 144 (81.8%)
	Sometimes 32 (18.2%)
Part 3: Practices related to the impact of Covid-19.
Are you scared to take your medication?	Yes 34 (19.3%)
	No 94 (53.4%)
	To some extent 48 (27.3%)
Did you stop taking your medication because of the pandemic?	Yes 28 (15.9%)
	No 138 (78.4%)
	To some extent 10 (5.7%)
Did you ask your doctor to change your disease-modifying therapy?	Yes 6 (3.4%)
	No 168 (95.5%)
	To some extent 2 (1.1%)
Did you have to change your appointment or miss it because of the curfew?	Yes 76 (43.2%)
	No 78 (44.3%)
	To some extent 22 (12.5%)
Did you have to change your appointment or miss it to avoid getting infected?	Yes 56 (31.8%)
	No 96 (54.5%)
	To some extent 24 (13.6%)
Did you avoid going to the hospital because of the pandemic despite having a relapse?	Yes 26 (14.8%)
	No 136 (77.3%)
	To some extent 12 (6.8%)
Did the pandemic lead to any change in your OPD, drug infusion, or medication refill?	Yes 62 (35.2%)
	No 82 (46.6%)
	To some extent 32 (18.2%)

Association between knowledge, attitudes, and healthcare practices among MS patients

We examined the correlation between knowledge, attitude, and healthcare practices. The mean knowledge score was 8.6±0.6, the mean attitude score was 8.5±0.7, and the mean score for the impact of the pandemic on healthcare was 11.1±3.6. Pearson's correlation coefficient revealed a moderate positive correlation between knowledge and attitude (r = 0.6). However, the correlation between knowledge and healthcare practices was weak (r = 0.06).

Discussion

Covid-19, as it ravages across the globe, has carried, alongside its wave of devastation, demand for new knowledge, and a dire need of novel public health policy measures. Despite the rapid accumulation of scientific knowledge regarding the microbiology of SARS-CoV-2, and also the pathogenesis and the clinical course of Covid-19, public health measures in many countries have crumbled. As policymakers around the world struggle to combat the rapid spread of the Covid-19 pandemic, they find themselves in unchartered territory, not only because of the laxity of the healthcare system, but also the influence of public tension accompanying a novel life-threatening disease, which frequently leads to wrong decision-making. The Covid-19 pandemic has blatantly exposed the vulnerabilities of the global healthcare system in terms of fragmented responses, unpreparedness, and poor sustainability [16]. The uncertainty around public health policies has also emerged as policymakers struggle to concurrently constrain the disease spread and ameliorate the consequential economic meltdown associated with some public health policies. Countries have thus applied different practices and policies to stifle the spread of the disease in its infancy and mitigate the imminent economic consequences. Social distancing, quarantine, and isolation, when stringent, have proved effective in containing the disease [17]. However, far from their economic impacts, these measures have surfaced various challenges in public health, which are partly fueled by the growing public tension due to misinformation, myths, and insufficiencies in healthcare [18]. Surveys conducted in different countries reported moderate to severe anxiety attributed to the pandemic in 23%, 19%, and 12% of the respondents from Saudi Arabia, Iran, and Spain, respectively [19-21]. Anxiety levels could be higher in patients with chronic diseases as mortality, in general, is higher in the population of people with chronic diseases [22]. Other studies of the general population revealed lower psychological well-being and higher scores of anxiety and depression compared to before Covid-19 pandemic [23]. The routine healthcare of patients with chronic diseases has also been adversely affected, especially when resource-deficient countries reallocate their meager resources to the Covid-19 pandemic, thereby disrupting the routine continuum of care [24]. In patients with MS, misconceptions about the risk of infection with a highly-contagious virus such as SARS-CoV-2 can lead to wrong decisions such as avoiding hospital visits when it is necessary or discounting medications. In dealing with these dynamic challenges, specific local measures that address the needs of a particular population are required. In instituting these measures, a clear exposure of the knowledge gap, attitudes related to Covid-19, and various behavioral practices have to be considered. In this study, we report these key issues with respect to MS patients and suggest possible interventions.

We interviewed a total of 176 respondents who completed the survey, out of whom 95.5% understood the symptomatology of Covid-19, 90% were following precautions instituted by the ministry of health, and 83% were obeying quarantine regulations. These findings reflect a high level of knowledge of Covid-19 symptoms and practice preventive measures among MS patients. These findings are also similar to those of other studies that were done in other countries [25-27]. However, the high level of knowledge in our study should be interpreted with caution, as all of our participants were recruited online through WhatsApp and Twitter platforms, which were somewhat undoubtedly among the major sources of information, especially during the curfew [28-30]. Most of our participants (64%) were Bachelor’s degree holders who may be reasonably assumed to have above-average knowledge. In this case, the level of knowledge in an all-inclusive MS population might have been slightly lower. Of all participants, 90% washed their hands regularly, 84% followed social distancing precautions, and 82% always stayed at home during the curfew. The high level of knowledge was, therefore, reflected in their attitudes towards reducing the risk of SARS-CoV-2 infection, as depicted by a moderately-positive Pearson’s correlation. Most participants did not stop taking their DMTs (78.4%), even though 27.3% of them experienced some anxiety towards SARS-CoV-2 infection. Although our participants had an appreciable level of knowledge and an overall good attitude towards Covid-19, there was still some level of anxiety among them. Fear and anxiety from taking disease-modifying therapy were present in 46% of the participants in this survey. Around 15% of the participants avoided going to the hospital despite experiencing relapse symptoms, which might have been accounted for by missed hospital appointments and drug infusions, or self-centered decisions to quit DMTs. Acute relapses, despite posing various challenges in the management of MS, can affect the progression of the disease and frequently leave patients with clinical or subclinical sequelae [31]. Other researchers elsewhere have also reported high levels of anxiety in some high-risk populations in even greater figures [32]. Although most MS patients did not stop DMTs, the proportion which stopped them is likely to be accommodated in the 95.5% of participants who did not raise the concern to their physicians, which suggests that their decision was likely self-centered. Of all, 54.5% of participants opted to change their appointments to avoid SARS-CoV-2 infection, although it was not clear if they missed important follow-ups that could negatively impact their health. Likewise, almost half (43.2%) of all participants changed their hospital appointments, this time because of the curfew. This highlights our concern that public health policies during the Covid-19 pandemic might have led to some other detrimental consequences in marginalized groups. Around 47% of participants missed drug infusion or medication refill schedules because of the curfew, patient’s choice, or irregularities in the healthcare system during the Covid-19 pandemic. These results emphasize the fact that the Covid-19 pandemic impacted patients with chronic diseases such as MS in several aspects, raising the need for developing feasible solutions to these groups and reforming the healthcare system in preparation for future pandemics. Our results also raise the need to promote innovative technologies such as telemedicine in delivering healthcare for such populations, especially in an era of a pandemic such as Covid-19, who are not only at high risk but might have other constraints such as neurological deficits, which may further hinder their mobility and access to healthcare [33-36]. Several researchers have spotlighted the potential role of telemedicine in providing healthcare services, especially to marginalized groups, including MS patients [37, 38] who are most likely to be affected by the Covid-19 pandemic, which should permanently be embedded in the traditional healthcare for future pandemics [39, 40]. More than half (52.3%) of the participants received their information from their physicians, which emphasizes the fact that physicians are the most trusted source of information for patients with chronic diseases such as MS. This also stresses on the utility of telemedicine in ensuring real-time communication of health information between patients and their doctors during pandemics. In a chronic autoimmune disease that needs long-term treatment like MS, the optimal timing and choice of disease-modifying therapy could be challenging, especially so during the Covid-19 pandemic. Furthermore, there are no clear guidelines, and it is left to the treating neurologist based on their own experience and anecdotal clinical reports. In a survey including physicians treating patients with MS, one of the neurologists replied to an open question: “This is the most difficult time I have seen in my 19 years of neurology” [14]. Fortunately, data are accumulating rapidly, and we are learning more about Covid-19. In the beginning of the pandemic, some experts recommended delaying treatment with some highly efficacious therapy such as Cladribine, Ocrelizumab, and Alemtuzumab [41]. However, recent data suggested that the outcome of patients with MS who get SARS-CoV-2 infection is not different from that of the general population [42]. Physicians should be vigilant to updates and recommendations regarding MS to guide their patients during the Covid-19 pandemic.

Conclusion

Our study explored the knowledge, attitudes, and various aspects of the impact of Covid-19 in the healthcare of people with MS. We found an overall good understanding of the Covid-19 pandemic, with the vast majority of patients following health precautions to mitigate the risk of SARS-CoV-2 infection. We also found that the Covid-19 pandemic has a significant impact on the healthcare of patients with MS. Some patients opted to stop their DMTs without medical advice; others missed hospital appointments, drug infusion or refills, and experienced relapse symptoms. Although it is still inconclusive whether Covid-19 has a worse clinical course in MS patients or not, the risk of SARS-CoV-2 infection is generally high, and the impact of Covid-19 due to risky behavioral practices because of the fear of SARS-CoV-2 infection may be far-reaching. In realizing that these consequences were partly attributed to the frailty of the healthcare system, we have suggested some solutions to them. As it is still unknown when the Covid-19 pandemic will come to an end, telemedicine adoption, probable home infusion options, and giving more time to address patient queries is the best way to minimize the impact of the pandemic on this vulnerable group of the society. Altogether, our results provide a framework for public policy actions in resolving problems associated with the impact of Covid-19 in MS patients residing in Saudi Arabia.

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

21 Aug 2020

PONE-D-20-22758

"Behavioral practices of  patients with Multiple Sclerosis during Covid-19 pandemic."

PLOS ONE

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 05 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Luigi Lavorgna

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1) Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2) Please amend either the title on the online submission form (via Edit Submission) or the title in the manuscript so that they are identical.

3) Please remove your figures from within your manuscript file, leaving only the individual TIFF/EPS image files, uploaded separately.  These will be automatically included in the reviewers’ PDF.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Revisions to PONE-D-20-22758

In the research article "Behavioral practices of patients with Multiple Sclerosis during Covid-19 pandemic." the Authors aimed to investigate knowledge, attitudes and behavioral practices related to Covid-19 among patients with MS . The main results revealed overall good knowledge and attitudes related to Covid-19 among MS patients. However, the healthcare impact was considerable, as 32% of the participants missed their hospital appointments, and another 15% had a relapse and did not refer the hospital because of the pandemic.

The Authors conclude that Covid-19 pandemic impacted patients with MS in several aspects, raising the need for developing feasible solutions and reforming the healthcare by promoting innovative technologies such as telemedicine in delivering healthcare for such populations who may be not only at high risk but might have other constraints such as neurological deficits, which may further hinder their mobility and access to healthcare.

The manuscript is well written and easy to read; methods are sound and conclusions supported by the results. However, some minor revisions are needed.

Abstract

Line 28: in the sentence “Therefore, this study aimed to behavioral practices ….” It seems that something is missing

Line 37: in the sentence “Furthermore, 15% of the participants had a relapse….” it should be specified that 15% had a relapse and did not go to the hospital because of the Covid-19 pandemic, otherwise it seems that the COVID-19 was responsible for the relapse

Introduction

Line 67: in addition to reference # 7, refer to the article by Ghajarzadeh M. “Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?” Neurol Sci. 2020

Line 75: in addition to reference #9, refer to the article by Zheng C et al “Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020

Line 98: Please delete the sentence “We also looked at the impact of the Covid-19 pandemic on the healthcare services for patients with MS.” since the methods were not designed to directly assess the impact on healthcare services for patients with MS

Line 99: Please move the sentence “This survey took place in June 2020, during the peak of the Covid-

19 pandemic in the Kingdom of Saudi Arabia” to the methods section

Study participants and recruitment

It is necessary to describe how privacy of the patients was protected

Line 114: the sentence “who were exclusively patients diagnosed with MS for one year or more and were living in Saudi Arabia” is a repetition and should be deleted

Data collection and statistical analysis

A translated version of the questionnaire should be available in this section, also as supplementary material

Results

If there were missing responses it should be specified at the beginning of the methods and numbers about the missing data should be given

Healthcare practices during the Covid-19 pandemic among MS patients

In this section could you provide answers stratified for disease-modifying therapy? It would be interesting to know whether patients on injectables drugs were less anxious than those on depletive therapy

Discussion

Percentages reported in the discussion are reversed or different with respect to those reported in the results section: it would be easier for the reader to follow the discussion with the same values reported in the results

Lines 258-260: the sentence “Around 21.6% of the participants avoided going to the hospital despite experiencing relapse symptoms” is not in agreement with results showing a 15% of patients experiencing a relapse (as reported in lines 187-188)

Lines 254-255: again in this sentence “Most participants did not stop taking their DMTs (78.4%), …..” the 78.8% is not in line with the results reported in line 184 “Of all participants, only 28 (15.9 %) stopped”; please explain this discrepancy.

Line 266-267: again the sentence ”…. 95.5% of participants who did not raise the concern to their physicians” the 95.5% is not in line with the results reported in line 182-183 (“only 6 (3.4%) participants asked their doctors to discontinue or change their disease-modifying therapy”)

Line 282: in addition to reference 32, please refer to please refer to these three articles:

1) Assessing disability and relapses in multiple sclerosis on tele-neurology by Moccia et al. Neurol Sci. 2020

2) Feasibility of Real Time Internet-Based Teleconsultation in Patients With Multiple Sclerosis: Interventional Pilot Study by D'Haeseleer et al. J Med Internet Res. 2020 Aug

3) Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic by Bonavita et al Neurol Sci 2020

Line 284: as a reference to support the sentence “Several researchers have spotlighted the potential role of telemedicine in providing healthcare services, especially to marginalized groups, including MS patients” add:

1) E-Health and multiple sclerosis: An update. Lavorgna et al. Mult Scler. 2018

2) E-health and multiple sclerosis. Matthews et al Curr Opin Neurol. 2020

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

7 Oct 2020

Abstract

Line 28: in the sentence “Therefore, this study aimed to behavioral practices ….” It seems that something is missing

Therefore, this study aimed to look at the behavioral practices related to Covid-19 among patients with MS .

The missing word “ look at” has been added.

Line 37: in the sentence “Furthermore, 15% of the participants had a relapse….” it should be specified that 15% had a relapse and did not go to the hospital because of the Covid-19 pandemic, otherwise it seems that the COVID-19 was responsible for the relapse

We added this information to clarify the sentence.“and did not go to the hospital because of the pandemic”

Introduction

Line 67: in addition to reference # 7, refer to the article by Ghajarzadeh M. “Are patients with multiple sclerosis (MS) at higher risk of COVID-19 infection?” Neurol Sci. 2020

Reference added.

Line 75: in addition to reference #9, refer to the article by Zheng C et al “Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination. CNS Drugs. 2020

Reference added.

Line 98: Please delete the sentence “We also looked at the impact of the Covid-19 pandemic on the healthcare services for patients with MS.” since the methods were not designed to directly assess the impact on healthcare services for patients with MS

Agree with you, deleted .

Line 99: Please move the sentence “This survey took place in June 2020, during the peak of the Covid-19 pandemic in the Kingdom of Saudi Arabia” to the methods section

Moved to method section 109,110 .

Study participants and recruitment

It is necessary to describe how privacy of the patients was protected

To ensure patients privacy ,no personal identifications were included in the form and responses were encrypted to protect the data. ( We added this sentence to the method section)

Line 114: the sentence “who were exclusively patients diagnosed with MS for one year or more and were living in Saudi Arabia” is a repetition and should be deleted

This sentence has been deleted.

Data collection and statistical analysis

A translated version of the questionnaire should be available in this section, also as supplementary material.

It is added as a supplementary material ,and most of the content of the questionnaire are available on Table 2 .

Results

If there were missing responses it should be specified at the beginning of the methods and numbers about the missing data should be given.

We received a total of 192 responses. After reviewing 16 responses were excluded because of duplication or missing responses. I added this information to the end of the method section.

Healthcare practices during the Covid-19 pandemic among MS patients

In this section could you provide answers stratified for disease-modifying therapy? It would be interesting to know whether patients on injectables drugs were less anxious than those on depletive therapy.

We tried to stratify the patients into low risk medication (injectable interferons ) and higher risk medication (all the other DMTs ) Interestingly there were no significant difference between the two groups . The sample sized is relatively small to yield a meaningful result from stratifying to injectable , oral , infusion or comparing the response to each drug alone.

Discussion

Percentages reported in the discussion are reversed or different with respect to those reported in the results section: it would be easier for the reader to follow the discussion with the same values reported in the results

Lines 258-260: the sentence “Around 21.6% of the participants avoided going to the hospital despite experiencing relapse symptoms” is not in agreement with results showing a 15% of patients experiencing a relapse (as reported in lines 187-188)

Corrected to 15 % of participants avoided going to the hospital despite having a relapse .

Lines 254-255: again in this sentence “Most participants did not stop taking their DMTs (78.4%), …..” the 78.8% is not in line with the results reported in line 184 “Of all participants, only 28 (15.9 %) stopped”; please explain this discrepancy.

The questions Did you stop taking your medication because of the pandemic ? could be answered as Yes ,to some extent or No.

78.% did not stop taking their medication , 15.9% answered Yes they stopped the medication and 5.7% stopped their medication to some extent .

We added this to the results section: (only 28 (15.9 %) completely stopped taking their medications because of the fear of Covid-19 and 10 (5.7)% stopped taking their medication to some extents which means poor compliance.)

Line 266-267: again the sentence ”…. 95.5% of participants who did not raise the concern to their physicians” the 95.5% is not in line with the results reported in line 182-183 (“only 6 (3.4%) participants asked their doctors to discontinue or change their disease-modifying therapy”)

This was the response to this question :

Yes 6 (3.4 %)

No 168 (95.5 %)

To some extent 2 (1.1 %)

I changed the sentence in results section to only 6 (3.4%) participants asked their doctors to discontinue or change their disease-modifying therapy and 2 (1.1%) stated that to some extent they raised concerns to their to doctors.

Line 282: in addition to reference 32, please refer to please refer to these three articles:

1) Assessing disability and relapses in multiple sclerosis on tele-neurology by Moccia et al. Neurol Sci. 2020

2) Feasibility of Real Time Internet-Based Teleconsultation in Patients With Multiple Sclerosis: Interventional Pilot Study by D'Haeseleer et al. J Med Internet Res. 2020 Aug

3) Digital triage for people with multiple sclerosis in the age of COVID-19 pandemic by Bonavita et al Neurol Sci 2020

Line 284: as a reference to support the sentence “Several researchers have spotlighted the potential role of telemedicine in providing healthcare services, especially to marginalized groups, including MS patients” add:

1) E-Health and multiple sclerosis: An update. Lavorgna et al. Mult Scler. 2018

2) E-health and multiple sclerosis. Matthews et al Curr Opin Neurol. 2020

All references are added .

Thanks for your time to review and valuable comments.

Submitted filename: Respnse to reviewers.docx

Click here for additional data file.

9 Oct 2020

"Behavioral practices of  patients with Multiple Sclerosis during Covid-19 pandemic."

PONE-D-20-22758R1

Dear Dr. Hind Alnajashi

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Luigi Lavorgna

Academic Editor

PLOS ONE

13 Oct 2020

PONE-D-20-22758R1

"Behavioral practices of patients with Multiple Sclerosis during Covid-19 pandemic "

Dear Dr. Alnajashi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Luigi Lavorgna

Academic Editor

PLOS ONE